沃森生物(300142.SZ):23價肺炎多糖疫苗產品呈快速增長
格隆匯2月15日丨沃森生物(300142.SZ)於2023年2月14日10:00-11:50接受機構調研時表示,鑑於新冠感染者易併發細菌性肺炎,隨着疫情管控政策變化,目前越來越多的人意識到通過接種肺炎球菌疫苗的重要性。公司相關產品的市場需求和關注度均持續提升,尤其23價肺炎多糖疫苗產品呈快速增長;13價肺炎結合疫苗市場競爭格局已非常明朗,公司產品已佔據50%以上的國內市場份額,並且有望進一步提高,未來隨着市場滲透率的提升,基於當前市場競爭格局、渠道鋪墊和市場推廣等情況,預計公司產品在可預見的時期內仍然能夠保持良好增長。公司會持續加強產品供應保障,及時滿足市場的接種需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.